-
Company Profile for Neuraptive Therapeutics, Inc.
Company Profile for Neuraptive Therapeutics, Inc.
Share
--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries.
Company: |
Neuraptive Therapeutics, Inc. |
||
|
|
||
Headquarters Address: |
2 Logan Square |
||
|
Suite 1930 |
||
|
Philadelphia, PA 19103 |
||
|
|
||
Main Telephone: |
617-794-6442 |
||
|
|
||
Website: |
|||
|
|
||
Type of Organization: |
Private |
||
|
|
||
Industry: |
Biotechnology |
||
|
|
||
Key Executives: |
EVP, Head of R&D: Evan Tzanis |
||
|
|
||
EVP, Head of R&D |
|
||
Contact: |
Evan Tzanis |
||
Phone: |
617-794-6442 |
||
Email: |
More News From Neuraptive Therapeutics, Inc.
Neuraptive Therapeutics Licenses Innovative Bioresorbable Nerve Stimulation Technology from Washington University in St. Louis
CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a clinical-stage biotech company focused on peripheral nerve injuries, announced today that it has secured an exclusive license from Washington University in St. Louis for a bioresorbable wireless electronic stimulation device. Developed by researchers at WashU Medicine in collaboration with Northwestern University, the technology delivers targeted electrical pulses to damaged nerves to speed up regeneration. The device is fully...
Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercialization
CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics today announced the appointment of Ulf Wiinberg to its Board of Directors and William “Bill” MacKenzie as Senior Vice President – Finance. Mr. Wiinberg is a seasoned biotechnology, pharmaceutical and healthcare industries executive with an extensive global career. As a member of the Board of Directors, he will contribute strategic guidance and industry expertise to support the Company’s development and commercialization strategy. Mr. W...
Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair
CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial...
